DNA topoisomerase I and II in cancer chemotherapy: update and perspectives.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

40 citing papers in PubMed.

1. Phase II study of the irinotecan (CPT-11), mitoxantrone and dexamethasone regimen in elderly patients with relapsed or refractory peripheral T-cell lymphoma.Cancer science · 2007
   Trial
2. Phase II study of the CPT-11, mitoxantrone and dexamethasone regimen in combination with rituximab in elderly patients with relapsed diffuse large B-cell lymphoma.Cancer science · 2006
   Trial
3. Phase II trial of CPT-11 in myelodysplastic syndromes with excess of marrow blasts.Leukemia · 2003
   Trial
4. Phase I study of sequentially administered topoisomerase I inhibitor (irinotecan) and topoisomerase II inhibitor (etoposide) for metastatic non-small-cell lung cancer.British journal of cancer · 1997
   Trial
5. Phase I and pharmacological study of sequential intravenous topotecan and oral etoposide.British journal of cancer · 1997
   Trial
6. Mutual regulation of MDM4 and TOP2A in cancer cell proliferation.Molecular oncology · 2019
   Article
7. Anthracyclines as Topoisomerase II Poisons: From Early Studies to New Perspectives.International journal of molecular sciences · 2018
   Review
8. Linalool Induces Cell Cycle Arrest and Apoptosis in Leukemia Cells and Cervical Cancer Cells through CDKIs.International journal of molecular sciences · 2015
   Article
9. Restoration of CBX7 expression increases the susceptibility of human lung carcinoma cells to irinotecan treatment.Naunyn-Schmiedeberg's archives of pharmacology · 2015
   Article
10. Mechanisms of Drug Resistance in Veterinary Oncology- A Review with an Emphasis on Canine Lymphoma.Veterinary sciences · 2015
    Review
11. Decreased camptothecin sensitivity of the stem-cell-like fraction of Caco2 cells correlates with an altered phosphorylation pattern of topoisomerase I.PloS one · 2014
    Article
12. DNA-based sensor for real-time measurement of the enzymatic activity of human topoisomerase I.Sensors (Basel, Switzerland) · 2013
    Article
13. Antitumor agents 294. Novel E-ring-modified camptothecin-4β-anilino-4'-O-demethyl-epipodophyllotoxin conjugates as DNA topoisomerase I inhibitors and cytotoxic agents.Bioorganic & medicinal chemistry · 2012
    Article
14. Prognostic values of filamin-A status for topoisomerase II poison chemotherapy.International journal of biological sciences · 2012
    Article
15. A multiscale dynamic model of DNA supercoil relaxation by topoisomerase IB.Biophysical journal · 2011
    Article
16. Voreloxin is an anticancer quinolone derivative that intercalates DNA and poisons topoisomerase II.PloS one · 2010
    Article
17. Preclinical results of camptothecin-polymer conjugate (IT-101) in multiple human lymphoma xenograft models.Clinical cancer research : an official journal of the American Association for Cancer Research · 2009
    Article
18. Gene expression profile of cervical and skin tissues from human papillomavirus type 16 E6 transgenic mice.BMC cancer · 2008
    Article
19. Antileukemia activity of the combination of an anthracycline with a histone deacetylase inhibitor.Blood · 2006
    Article
20. Deficiency in 3'-phosphoglycolate processing in human cells with a hereditary mutation in tyrosyl-DNA phosphodiesterase (TDP1).Nucleic acids research · 2005
    Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as